BNTC vs. VERA, COGT, JANX, PGEN, ETNB, XERS, ABCL, EVO, COLL, and NTLA
Should you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Vera Therapeutics (VERA), Cogent Biosciences (COGT), Janux Therapeutics (JANX), Precigen (PGEN), 89BIO (ETNB), Xeris Biopharma (XERS), AbCellera Biologics (ABCL), Evotec (EVO), Collegium Pharmaceutical (COLL), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry.
Benitec Biopharma vs. Its Competitors
Benitec Biopharma (NASDAQ:BNTC) and Vera Therapeutics (NASDAQ:VERA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.
Benitec Biopharma has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.
Benitec Biopharma's return on equity of -38.26% beat Vera Therapeutics' return on equity.
Benitec Biopharma currently has a consensus price target of $26.00, indicating a potential upside of 85.85%. Vera Therapeutics has a consensus price target of $63.00, indicating a potential upside of 151.20%. Given Vera Therapeutics' higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Benitec Biopharma.
52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by insiders. Comparatively, 16.3% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Vera Therapeutics had 10 more articles in the media than Benitec Biopharma. MarketBeat recorded 14 mentions for Vera Therapeutics and 4 mentions for Benitec Biopharma. Vera Therapeutics' average media sentiment score of 1.36 beat Benitec Biopharma's score of 1.18 indicating that Vera Therapeutics is being referred to more favorably in the news media.
Benitec Biopharma has higher revenue and earnings than Vera Therapeutics. Benitec Biopharma is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Vera Therapeutics beats Benitec Biopharma on 7 of the 13 factors compared between the two stocks.
Get Benitec Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benitec Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:BNTC) was last updated on 9/10/2025 by MarketBeat.com Staff
Free BNTC Stock Alerts